Post Office Boosts Breast Cancer Stamp

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 4
Volume 8
Issue 4

WASHINGTON-Sales of the 40-cent Breast Cancer stamp generated $5.2 million for breast cancer research in the first 7 months following its release in July 1998. The US Postal Service plans a sales campaign tied to Mother’s Day, and it will promote the stamp in partnership with the Revlon Run/Walk for Women fund-raiser in Los Angeles and New York City

WASHINGTON—Sales of the 40-cent Breast Cancer stamp generated $5.2 million for breast cancer research in the first 7 months following its release in July 1998. The US Postal Service plans a sales campaign tied to Mother’s Day, and it will promote the stamp in partnership with the Revlon Run/Walk for Women fund-raiser in Los Angeles and New York City

Funds from the stamp’s sale above the regular cost of a first-class stamp, now 33 cents, go the National Institutes of Health (70%) and Department of Defense (30%) for breast cancer research

Articles in this issue
PDT Under Study for High-Grade Dysplasia in Barrett’s Esophagus
Importance of Assessing, Treating Pain in the Cancer Patient
Post Office Boosts Breast Cancer Stamp
RT After Mastectomy Reduces Recurrence Risk
Who Smokes? A Profile of Smokers in the US
Elderly May Do Well With Tamoxifen Without Surgery
Managing Respiratory Symptoms of Advanced Cancer
Results of Prevention Trials in Prostate, Colon, Breast Cancer
NABCO ‘Celebrates Life’ and Honors Breast Cancer Survivors at Luncheon
Multimodal Screening Strategy for Ovarian Cancer
What We’re Learning About the Analgesic Effects of Cannabinoids
Modified Respiratory Therapy for Advanced Cancer Patients
‘Screen for Life’ Campaign Promotes Colorectal Tests
Modeling Cancer Risks ‘Problematic But Still Useful’
Cachexia Patients Gain Weight With EPA and Diet Supplement
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches

Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches

Ariana Pelosci
August 14th 2025
Article

Tran Ho, DO, FSSO, FACS, discussed how she found her passion in breast surgical oncology and how her mentors helped her achieve success.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Obesity and weight gain are associated with adverse outcomes following breast cancer diagnosis.

GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer

Sherry Shen, MD;Bethina Liu, MD;Chad Fanti, MD;Maria Bromberg, MPH;Yuan Chen, PhD;Cassandra Chang;Neil M. Iyengar, MD
August 12th 2025
Article

Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

DCISionRT Enhances DCIS Risk Stratification Beyond Clincopathology

Roman Fabbricatore
August 6th 2025
Article

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic

Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic

Ariana Pelosci
July 29th 2025
Article

Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.